This HCA Healthcare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Transcript: Guardian Pharmacy Service Q2 2026 Earnings Conference Call

Guardian Pharmacy Service (NYSE:GRDN) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive

Joint Commission Enterprise Names Ken Grubbs, DNP, MBA, RN, Chief Operating Officer

Joint Commission announced the appointment of Ken Grubbs, DNP, MBA, RN, as chief operating officer, marking the first time a nurse has held this position in the organization's 75-year history. Dr. Grubbs, who brings over two decades of healthcare leadership experience across clinical operations, patient safety, and quality improvement, will assume the role on January 1, 2027, succeeding James Merlino, MD, who becomes president and CEO.

TD Cowen Maintains Buy on HCA Healthcare, Raises Price Target to $460

TD Cowen analyst Ryan Langston maintains HCA Healthcare (NYSE:HCA) with a Buy and raises the price target from $431 to $460.

RBC Capital Maintains Outperform on HCA Healthcare, Raises Price Target to $496

RBC Capital analyst Ben Hendrix maintains HCA Healthcare (NYSE:HCA) with a Outperform and raises the price target from $435 to $496.

Shares of semiconductor and chip companies are trading lower as rising inflation concerns and elevated energy prices fuel expectations for further Fed rate hikes. Elevated borrowing costs could pressure semiconductor manufacturing and AI infrastructure investments while straining customer budgets. The Philadelphia Semiconductor Index (SOX) has declined for seven consecutive trading sessions, matching its longest losing streak since the 2008 financial crisis.

Got $1,000? 1 Top Stock to Buy Amid the Semiconductor Sell-Off Before It Triples by 2030

Marvell Technology is recommended as a strong buy opportunity following a semiconductor sector selloff triggered by concerns from Intel and Broadcom CEOs about capital constraints for AI infrastructure. Despite near-term headwinds, Marvell is positioned for exceptional growth with projected revenue CAGR of 55-60% through fiscal 2031, driven by demand for custom AI chips and networking components. Analysts project the stock could reach $885 by 2031, representing 261% upside from current levels, potentially turning a $1,000 investment into over $3,600.